Assessment of clinical efficacy of traditional Chinese medicine for the management of primary dysmenorrhea in the UK
A protocol of systematic review
Ming-ming Fu, MDa, Xiang-dong Meng, MMb,∗

Abstract
Background: This study aims to appraise the clinical efficacy of traditional Chinese medicine (TCM) for the management of patients with primary dysmenorrhea (PD) in the UK.

Methods: We will comprehensively search electronic databases (Cochrane Library, PUBMED/MEDLINE, EMBASE, PsycINFO, AMED, Web of Science, and CNKI) and additional resources for original articles on randomized controlled trials published in English, Chinese, German, Spanish, Korean and Japanese. Outcomes will be the pain intensity, pain duration, menstrual cramps, amount of bleeding, and severity of dysmenorrhea symptoms, quality of life, and adverse events. Two authors will independently check all citations, extract data, and assess study quality. All potential conflicts will be solved through discussion by consulting another experienced author. A narrative synthesis will summarize the characteristics and findings of eligible trials. If it is possible, we will also pool the data and carry out meta-analysis.

Results: The available evidence of the clinical efficacy of TCM for the treatment of PD in UK will be assessed through outcome measurements.

Conclusion: The findings of this study will determine whether or not TCM is effective and safe for the treatment of PD in UK.

OSF registration number: osf.io/jyc95.

Abbreviations: PD = primary dysmenorrhea, RCTs = randomized controlled trials, TCM = traditional Chinese medicine.

Keywords: efficacy, primary dysmenorrhea, traditional Chinese medicine

1. Introduction
Primary dysmenorrhea (PD) is a prevalent gynecological health problem among adolescent girls and adult women.[1–3] It is characterized by painful cramps in the lower abdomen during menstruation period.[4,5] Patients with PD may also experience vomiting, nausea, diarrhea, fatigue, nervousness and dizziness.[2–7] It is reported that its incidence varies from 45% to 72% of all reproductive age women; and this figure can reach as high as 93% of adolescent girls.[8] If it can not be treated very well, it can prevent those people from participating in their daily activities.[9,10] Although a variety of managements are reported to treat PD, their efficacy is still limited and some have severe adverse events.[11–13] Thus, it is necessary to explore alternative therapy with fewer adverse events for treating PD.

Traditional Chinese medicine (TCM) has been used for the management of PD widely in China.[14–17] It consists of herbal medicine, acupuncture, moxibustion, Tui-na, and any others.[14–22] Studies suggested that TCM can manage PD in UK.[23,24] However, there is still insufficient evidence to support the clinical efficacy and safety of TCM for PD in UK. Thus, this study will explore the clinical efficacy and safety of TCM for the treatment of PD in UK systematically and comprehensively.

2. Methods

2.1. Study registration
This study protocol was registered on OSF (osf.io/jyc95). It is being reported based on the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement.
2.2. Eligibility criteria

2.2.1. Types of population. We will include original randomized controlled trials (RCTs) of females in UK who had PD disorder, in spite of any age, gender, and economic status.

2.2.2. Types of study. This study will only consider RCTs that investigated the clinical efficacy and safety of TCM in treating PD for inclusion. We will exclude any other studies, except RCTs.

2.2.3. Types of exposure. We will include RCTs that utilized TCM (including Chinese herbal medicine, acupuncture, moxibustion, et al) as major treatment.

2.2.4. Types of comparators. There is no restrictions to the control. However, we will exclude studies that used combined therapy with any forms of TCM.

2.2.5. Types of outcomes. Outcomes are the pain intensity, pain duration, menstrual cramps, amount of bleeding, and severity of dysmenorrhea symptoms, quality of life, and adverse events.

2.3. Information sources
We will carry out a comprehensive search in electronic databases from the beginning to the current date (Cochrane Library, PUBMED/MEDLINE, EMBASE, PsychINFO, AMED, and Web of Science, and CNKI) and additional resources (reference lists of all included studies and relevant reviews, and websites of clinical trial registry) for original trials on RCTs published in English, Chinese, German, Spanish, Korean and Japanese. The search strategy for Cochrane Library is provided in Table 1. We will adapt similar search strategy for other electronic databases.

2.4. Selection process
Two authors will independently perform study selection process, respectively. First, titles and abstracts of all identified records will be screened, and all irrelevant studies will be removed. Then, full texts of potentially eligible articles will be read against all inclusion criteria and they will be determined to be included. Any divergence will be solved by discussion. We will present the selection process results in a flow chart.

2.5. Data extraction process
Two authors will independently extract data using a standardized form. For each included study, the following data will be extracted: title, authors, time of publication, location, study design, setting, and methods, study period, number of patients in each group, patient characteristics, interventions, controls, statistical methods, outcomes, main results/effect estimates, funding information, and conflict of interest. Any conflicts will be solved through discussion until consensus is reached. Missing or insufficient information will be obtained by contacting primary study authors via email or fax.

2.6. Study quality assessment
Two authors will independently rate study quality of included RCTs with respect to methodological criteria of Cochrane Risk of Bias Tool. It has 7 items, and each item is divided into 3 levels: low, unclear and high risk of bias. Any disagreements will be settled down by discussion with the help of a third author.

2.7. Quality of evidence assessment
Two authors will appraise quality of evidence for each outcome using Grades of Recommendation, Assessment, Development and Evaluation approach.[23] Any divergence will be solved by a third author through discussion and a final decision will be made.

2.8. Statistical analysis
This study will conduct statistical analysis using RevMan 5.3 software. The results of quantitative trials will be estimated as frequencies, percentages, means, relative risks, or odds ratios.

| Table 1 |
| Search strategy sample of Cochrane Library. |

| Number | Search terms |
|--------|--------------|
| 1      | MeSH descriptor: (Dysmenorrhea) explode all trees |
| 2      | (((dysmenorrhea) or (menstrual pain) or (painful menstruation) or (primary dysmenorrhea) or (pain intensity))):ti, ab, kw |
| 3      | Or 1–2 |
| 4      | (UK) explode all trees |
| 5      | ((United Kingdom) or (Great Britain) or (Britain) or (Northern Ireland) or (U.K.)):ti, ab, kw |
| 6      | Or 4–5 |
| 7      | (traditional Chinese medicine) explode all trees |
| 8      | MeSH descriptor: (acupuncture) explode all trees |
| 9      | MeSH descriptor: (electroacupuncture) explode all trees |
| 10     | MeSH descriptor: (acupuncture analgesia) explode all trees |
| 11     | MeSH descriptor: (acupuncture therapy) explode all trees |
| 12     | MeSH descriptor: (moxibustion) explode all trees |
| 13     | (((Chinese medicine) or (herbal medicine) or (moxibustion) or (tui na) or (Gigong) or (cupping therapy) or (acupuncture) or (manual acupuncture) or (needling) or (acupuncture) or (meridian) or (auricular needle) or (ear acupuncture) or (scrap acupuncture) or (abdominal acupuncture)):ti, ab, kw |
| 14     | Or 7–13 |
| 15     | MeSH descriptor: (randomized controlled trials) explode all trees |
| 16     | (((randomly) or (random) or (blind) or (allocation) or (concealment) or (placebo) or (sham) or (clinical) or (control) or (study)) or (trial)):ti, ab, kw |
| 17     | Or 15–16 |
| 18     | 3 and 6 and 14 and 17 |
with 95% confidence intervals. The results of qualitative trials will be presented according to the descriptive characteristics and main themes. We will check statistical heterogeneity across included RCTs using $I^2$ test. Value of $I^2 \leq 50\%$ means homogeneity, and we will use a fixed-effects model to pool the data. Value of $I^2 > 50\%$ exerts obvious heterogeneity, and we will utilize a random-effects model to synthesize the data. If sufficient data on the same outcome measurement are available, we will plan to carry out a meta-analysis based on the enough similarity in study information, patient characteristics, interventions, and controls. If it is not possible to perform a meta-analysis, we will narratively synthesize outcome data, and characteristics and results of included RCTs will be descriptively summarized in evidence tables.

In addition, we will undertake a subgroup analysis to investigate the possible factors that may result in obvious heterogeneity based on the different study information, patient characteristics, treatments, and comparators. If necessary, we will carry out a sensitivity analysis to examine the stability of merged results by eliminating low quality RCTs. If more than 10 studies on the same outcome are included, we will perform a funnel plot and Egger’s regression test to identify if there is any possible reporting bias.\(^{[26,27]}\)

2.9. Ethics and dissemination

This study protocol does not need ethical approval since it is conducted based on published data. It will be published on a peer-reviewed journal or a conference meeting.

3. Discussion

This study aims to assess the clinical efficacy of TCM in treating PD in UK population. So far, there is no up-to-date analysis that specifically merges results from different RCTs on TCM for PD systematically and comprehensively. Thus, it is very necessary to explore this issue so that insights can be utilized to inform clinical practice and decision makers. However, there may be several limitations exist in this study. First, this study only focuses on UK population, which may limit the number of eligible studies. Second, some included RCTs may have small sample size. Third, some included studies may have poor methodological quality. Finally, there may be remarkable heterogeneity across the included trials. All those limitations may affect the findings of this study.

Author contributions

Conceptualization: Ming-ming Fu, Xiang-dong Meng.
Data curation: Ming-ming Fu, Xiang-dong Meng.
Formal analysis: Ming-ming Fu, Xiang-dong Meng.
Funding acquisition: Ming-ming Fu.
Investigation: Xiang-dong Meng.
Methodology: Ming-ming Fu, Xiang-dong Meng.
Project administration: Xiang-dong Meng.
Resources: Ming-ming Fu, Xiang-dong Meng.
Software: Ming-ming Fu.
Supervision: Xiang-dong Meng.
Validation: Ming-ming Fu, Xiang-dong Meng.
Visualization: Ming-ming Fu, Xiang-dong Meng.
Writing – original draft: Ming-ming Fu, Xiang-dong Meng.
Writing – review & editing: Ming-ming Fu, Xiang-dong Meng.

References

\[1\] Koninckx PR, Ussia A, Adamyan L, et al. Primary dysmenorrhea. J Obstet Gynaecol Can 2017;39:578–9.
\[2\] Kennedy S. Primary dysmenorrhea. Lancet 1997;349:1116.
\[3\] De Sanctis V, Soliman A, Bernasconi S, et al. Primary dysmenorrhea in adolescents: prevalence, impact and recent knowledge. Pediatr Endocrin Rev 2015;13:512–20.
\[4\] Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006;108:428–41.
\[5\] Dory E, Attaran M. Managing primary dysmenorrhea. J Pediatr Adolesc Gynecol 2006;19:341–4.
\[6\] Perheentupa A, Erkkola R, Koulu M. Primary dysmenorrhea painful menstruation. Duodecim 2005;121:3411–8.
\[7\] Grandi G, Ferrari S, Xholli A, et al. Prevalence of menstrual pain in young women: what is dysmenorrhea? J Pain Res 2012;5:169–74.
\[8\] Yang J, Chen J, Lao L, et al. Effectiveness study of moxibustion on pain relief in primary dysmenorrhea: study protocol of a randomized controlled trial. Evid Based Complement Alternat Med 2014;2014:434978.
\[9\] Gummaräes I, Pövoa AM. Primary dysmenorrhea: assessment and treatment. Rev Bras Ginecol Obstet 2020;42:501–7.
\[10\] Lefebvre G, Pinsoneault O, Antao V, et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 2005;27:1117–46.
\[11\] Jhunggrifir M, Taebi M, Dolantzi M. The effect of Cinnamon on primary dysmenorrhea: a randomized, double-blind clinical trial. Complement Ther Clin Pract 2018;33:56–60.
\[12\] Ozgoli G, Goli M, Moattar F. Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. J Altern Complement Med 2009;15:129–32.
\[13\] Shoibeir F, Nazari S, Nazari S, et al. Effect of Menstrugole on primary dysmenorrhea: a randomized clinical trial. Obstet Gynecol Sci 2018;6:1484–7.
\[14\] Zhang F, Sun M, Han S, et al. Acupuncture for primary dysmenorrhea: an overview of systematic reviews. Evid Based Complement Alternat Med 2018;2018:8791538.
\[15\] Yang M, Chen X, Bo L, et al. Moxibustion for pain relief in patients with primary dysmenorrhea: a randomized controlled trial. PLoS One 2017;12:e0170952.
\[16\] Liu T, Yu JN, Cao BY, et al. Acupuncture for primary dysmenorrhea: a meta-analysis of randomized controlled trials. Altern Ther Health Med 2017;23:46–53.
\[17\] Yu A. Complementary and alternative treatments for primary dysmenorrhea in adolescents. Nurse Pract 2014;39:1–2.
\[18\] Xu L, Xie T, Shen T, et al. Effect of Chinese herbal medicine on primary dysmenorrhea: a protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e17191.
\[19\] Gong L, Jia C, Zhang H, et al. Wenjing decoction (herbal medicine) for the treatment of primary dysmenorrhea: a systematic review and meta-analysis. Arch Gynecol Obstet 2017;296:679–89.
\[20\] Seo J, Lee D, Jo HG. Dangguijagyag-san for primary dysmenorrhea: a protocol for systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019;98:e18345.
\[21\] Leen J, Jo J, Kwon CY, et al. Herbal medicine (Hydrobucuksue-tang or Xuefu Zhuyu decoction) for treating primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019;98:e14170.
\[22\] Guo AS, Meng QY. Acupuncture combined with spinal tui na for treatment of primary dysmenorrhea in 30 cases: randomized controlled trial. J Tradit Chin Med 2008;28:7–9.
\[23\] Aftarsoogu UO, Igwe SE, Tabanizi-Ochiogu CS. Effectiveness of SP6 (Sanyinjiao) acupuncture for relief of primary dysmenorrhea symptoms: a systematic review with meta- and sensitivity analyses. Complement Ther Clin Pract 2016;25:92–105.
\[24\] Kennedy S, Jin X, Yu H, et al. Randomized controlled trial assessing a traditional Chinese medicine remedy in the treatment of primary dysmenorrhea. Fertil Steril 2006;86:762–4.
\[25\] 2013;Schünemann H, Brozek J, Guyatt G, et al. GRADE handbook for rating quality of evidence and strength of recommendations. Updated October. The GRADE Working Group.
\[26\] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect publication bias on meta-analyses. BMJ 2000;320:1574–7.
\[27\] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

Fu and Meng Medicine (2020) 99:47 www.md-journal.com